{"filing":{"accession_number":"0001193125-26-270227","cik":"0001612042","ticker":"ASND","company_name":"Ascendis Pharma A/S","form":"6-K","filing_date":"2026-06-15","report_date":null,"primary_document":"d48156d6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1612042/000119312526270227/d48156d6k.htm"},"events":[{"id":12237,"run_id":10802,"accession_number":"0001193125-26-270227","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The 6-K discloses Week 182 data from the completed Phase 3 PaTHway Trial for TransCon PTH (palopegteriparatide), demonstrating sustained efficacy and safety in hypoparathyroidism over three-and-a-half years. This is a material clinical milestone—positive Phase 3 trial results supporting regulatory approval and commercial viability—but does not fit the discrete event categories (not an earnings release, M\u0026A activity, executive change, or financial obligation). It is a material operational/clinical development that would affect investor assessment of the product's regulatory and commercial prospects.","company_name":"Ascendis Pharma A/S","ticker":"ASND","filing_date":"2026-06-15","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":9040,"accession_number":"0001193125-26-270227","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The 6-K discloses Week 182 data from the completed Phase 3 PaTHway Trial for TransCon PTH (palopegteriparatide), demonstrating sustained efficacy and safety in hypoparathyroidism over three-and-a-half years. This is a material clinical milestone—positive Phase 3 trial results supporting regulatory approval and commercial viability—but does not fit the discrete event categories (not an earnings release, M\u0026A activity, executive change, or financial obligation). It is a material operational/clinical development that would affect investor assessment of the product's regulatory and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T02:26:53.759587+00:00","company_name":"Ascendis Pharma A/S","ticker":"ASND","filing_date":"2026-06-15"}]}